Gauthier S, Wirth Y, Möbius H J
MCSA Alzheimer's Disease Research Unit, McGill Centre for Studies in Aging, Quebec, Canada.
Int J Geriatr Psychiatry. 2005 May;20(5):459-64. doi: 10.1002/gps.1341.
Behavioural symptoms are common in moderate to severe Alzheimer's disease (AD). We have analysed the databases of two randomised studies with regard to the effects of memantine treatment on behavioural symptoms, measured using the 12-item version of the Neuropsychiatric Inventory (NPI).
The monotherapy study (memantine only) reported by Reisberg et al. (2003) involved 252 patients with baseline MMSE total score of between 3 and 14, whereas the combination study (memantine and donepezil) reported by Tariot et al. (2004) comprised 404 patients with MMSE scores of between 5 and 14. In both studies, patients received 10 mg memantine b.i.d. or matching placebo, and lived in the community.
For both studies NPI total and individual domains scores were analysed in the ITT population. For the monotherapy study a dichotomised analysis was performed separately for patients who had behavioural symptoms at baseline and for those without pre-existing symptoms. Furthermore, a factor analysis was used to identify any behavioural clusters within the patient population.
In both studies, the change in NPI total scores at endpoint was consistently in favour of memantine treatment, reaching statistical significance in the combination study (p = 0.002). Memantine treatment showed a significant beneficial effect in comparison to placebo treatment in the NPI agitation/aggression domain in both studies (p = 0.008; p = 0.001). The dichotomised analysis of the monotherapy study showed that there was significantly less agitation/aggression emerging in the memantine-treated group compared to placebo (p = 0.003). Factor analysis showed that hyperactivity accounted for 27% of the data variance.
Memantine has a beneficial effect on the behavioural symptoms of patients with moderate to severe AD, with the most pronounced effect on agitation/aggression.
行为症状在中度至重度阿尔茨海默病(AD)中很常见。我们分析了两项随机研究的数据库,以探讨美金刚治疗对行为症状的影响,这些症状使用12项版神经精神科问卷(NPI)进行测量。
Reisberg等人(2003年)报告的单药治疗研究(仅美金刚)纳入了252例基线简易精神状态检查表(MMSE)总分在3至14分之间的患者,而Tariot等人(2004年)报告的联合治疗研究(美金刚与多奈哌齐)包含404例MMSE评分在5至14分之间的患者。在两项研究中,患者均接受每日两次10mg美金刚或匹配的安慰剂治疗,并生活在社区中。
对两项研究的意向性分析(ITT)人群中的NPI总分及各个领域得分进行分析。对于单药治疗研究,分别对基线时有行为症状的患者和无既往症状的患者进行二分法分析。此外,采用因子分析来识别患者群体中的任何行为聚类。
在两项研究中,终点时NPI总分的变化始终有利于美金刚治疗,在联合治疗研究中达到统计学显著性(p = 0.002)。在两项研究中,与安慰剂治疗相比,美金刚治疗在NPI激越/攻击领域均显示出显著的有益效果(p = 0.008;p = 0.001)。单药治疗研究的二分法分析表明,与安慰剂相比,美金刚治疗组出现的激越/攻击行为明显更少(p = 0.003)。因子分析表明,多动占数据方差的27%。
美金刚对中度至重度AD患者的行为症状有有益作用,对激越/攻击行为的影响最为明显。